Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).

The deal comprises cash and cash equivalents worth $14m (Rs1.15bn) in the acquired business representing an enterprise value of $231m (Rs18.85bn).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment.

Holding a presence in the cosmetic dermatology sector, Curatio’s portfolio comprises more than over 50 brands that are commercialised in India.

The portfolio includes brands such as Tedibar, Atogla, Spoo, B4 Nappi and Permite.

Torrent Pharmaceuticals director Aman Mehta said: “We are delighted to enter into this deal with Curatio.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The acquisition offers Torrent the opportunity to enhance its presence in dermatology with a differentiated portfolio and is a strong strategic fit.

“Curatio has built a commendable set of high market share brands in cosmetic and pediatric dermatology that we look forward to adding to our product offerings.”

Subject to necessary conditions, the deal is anticipated to conclude in a month.

A flagship company of the Torrent Group, Torrent Pharmaceuticals is a speciality-focused firm with more than 74% of its revenue from chronic and sub-chronic therapies in India.

Having a presence in 40 countries, the company has seven manufacturing plants. Among these facilities, four are approved by the US Food and Drug Administration (FDA).

Torrent R&D infrastructure employs over 800 scientists.